Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds

Br J Pharmacol. 2000 Aug;130(8):1933-43. doi: 10.1038/sj.bjp.0703462.

Abstract

Replacement of the carboxylic acid group of PGF(2alpha) with the non-acidic substituents hydroxyl (-OH) or methoxy (-OCH(3)) resulted in an unexpected activity profile. Although PGF(2alpha) 1-OH and PGF(2alpha) 1-OCH(3) exhibited potent contractile effects similar to 17-phenyl PGF(2alpha) in the cat lung parenchymal preparation, they were approximately 1000 times less potent than 17-phenyl PGF(2alpha) in stimulating recombinant feline and human FP receptors. In human dermal fibroblasts and Swiss 3T3 cells PGF(2alpha) 1-OH and PGF(2alpha) 1-OCH(3) produced no Ca(2+) signal until a 1 microM concentration was exceeded. Pretreatment of Swiss 3T3 cells with either 1 microM PGF(2alpha) 1-OH or PGF(2alpha) 1-OCH(3) did not attenuate Ca(2+) signal responses produced by PGF(2alpha) or fluprostenol. In the rat uterus, PGF(2alpha) 1-OH was about two orders of magnitude less potent than 17-phenyl PGF(2alpha) whereas PGF(2alpha) 1-OCH(3) produced only a minimal effect. Radioligand binding studies on cat lung parenchymal plasma membrane preparations suggested that the cat lung parenchyma does not contain a homogeneous population of receptors that equally respond to PGF(2alpha)1-OH, PGF(2alpha)1-OCH(3), and classical FP receptor agonists. Studies on smooth muscle preparations and cells containing DP, EP(1), EP(2), EP(3), EP(4), IP, and TP receptors indicated that the activity of PGF(2alpha) 1-OH and PGF(2alpha) 1-OCH(3) could not be ascribed to interaction with these receptors. The potent effects of PGF(2alpha) 1-OH and PGF(2alpha) 1-OCH(3) on the cat lung parenchyma are difficult to describe in terms of interaction with the FP or any other known prostanoid receptor.

MeSH terms

  • 3T3 Cells
  • Animals
  • Binding, Competitive / drug effects
  • COS Cells
  • Calcium / metabolism
  • Cats
  • Cell Line
  • DNA, Recombinant
  • Dinoprost / analogs & derivatives*
  • Dinoprost / chemistry*
  • Dinoprost / pharmacology*
  • Dose-Response Relationship, Drug
  • Female
  • Guinea Pigs
  • Humans
  • In Vitro Techniques
  • Mice
  • Muscle Contraction / drug effects
  • Muscle, Smooth / drug effects
  • Muscle, Smooth / physiology
  • Prostaglandin D2 / metabolism
  • Prostaglandins F, Synthetic / pharmacology
  • Rabbits
  • Radioligand Assay
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Epoprostenol
  • Receptors, Prostaglandin / genetics
  • Receptors, Prostaglandin / metabolism
  • Receptors, Prostaglandin E / genetics
  • Receptors, Prostaglandin E / metabolism
  • Receptors, Prostaglandin E, EP1 Subtype
  • Receptors, Prostaglandin E, EP2 Subtype
  • Receptors, Prostaglandin E, EP3 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype
  • Receptors, Thromboxane / metabolism
  • Structure-Activity Relationship

Substances

  • DNA, Recombinant
  • PTGER1 protein, human
  • PTGER2 protein, human
  • PTGER3 protein, human
  • PTGER4 protein, human
  • PTGIR protein, human
  • Prostaglandins F, Synthetic
  • Ptger1 protein, mouse
  • Ptger1 protein, rat
  • Ptger2 protein, mouse
  • Ptger2 protein, rat
  • Ptger3 protein, mouse
  • Ptger3 protein, rat
  • Ptger4 protein, mouse
  • Ptger4 protein, rat
  • Ptgir protein, mouse
  • Ptgir protein, rat
  • Receptors, Epoprostenol
  • Receptors, Prostaglandin
  • Receptors, Prostaglandin E
  • Receptors, Prostaglandin E, EP1 Subtype
  • Receptors, Prostaglandin E, EP2 Subtype
  • Receptors, Prostaglandin E, EP3 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype
  • Receptors, Thromboxane
  • prostaglandin F2alpha receptor
  • fluprostenol
  • 17-phenylprostaglandin F2alpha
  • Dinoprost
  • Prostaglandin D2
  • Calcium